Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tramadol (Primary) ; Tramadol (Primary)
  • Indications Premature ejaculation
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch Health Companies; Biovail Technologies

Most Recent Events

  • 31 Jul 2022 This trial has been completed in Spain and France, according to European Clinical Trials Database record.
  • 22 Apr 2015 Primary endpoint 'Increase in IELT (Intravaginal ejaculatory time) for 89 mg dose' has been met, according to the Aytu Bioscience company pipeline.
  • 22 Apr 2015 Primary endpoint 'Premature Ejaculation Profile questionnaire' has been met, according to an Aytu Bioscience company pipeline.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top